We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aerie Pharmaceuticals Inc | NASDAQ:AERI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 15.25 | 15.24 | 14.79 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 12, 2017 (April 12, 2017)
Aerie Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-36152 | 20-3109565 | ||
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(I.R.S. Employer
Identification Number) |
2030 Main Street, Suite 1500
Irvine, California 92614
(Address of principal executive offices) (Zip code)
Registrants telephone number, including area code: (949) 526-8700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
EXPLANATORY NOTE
Aerie Pharmaceuticals, Inc. (the Company) is furnishing this Amendment No. 1 to its Current Report on Form 8-K (Amendment No. 1) furnished with the SEC on April 12, 2017 (the Original Form 8-K), to refurnish the slides describing the six-month topline results of Rocket 4 because Slide 9 in Exhibit 99.2 included in the Original Form 8-K included only the Companys logo. The slides presented by management and available on the Companys website (aeriepharma.com) remain unchanged.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit shall be deemed to be furnished, and not filed:
99.1 | Rhopressa TM (netarsudil ophthalmic solution) 0.02% Rocket 4 Phase 3 6-Month Topline Results. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AERIE PHARMACEUTICALS, INC. | ||||||
Date: April 12, 2017 | By: | /s/ Richard J. Rubino | ||||
Richard J. Rubino | ||||||
Chief Financial Officer |
EXHIBIT INDEX
Exhibit |
Description |
|
99.1 | Rhopressa TM (netarsudil ophthalmic solution) 0.02% Rocket 4 Phase 3 6-Month Topline Results. |
1 Year Aerie Pharmaceuticals Chart |
1 Month Aerie Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions